Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants - Trial NCT05764265
Access comprehensive clinical trial information for NCT05764265 through Pure Global AI's free database. This Phase 2 trial is sponsored by Novartis Pharmaceuticals and is currently Recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novartis Pharmaceuticals
Novartis
Timeline & Enrollment
Phase 2
Mar 27, 2023
Sep 29, 2025
Primary Outcome
Number of patients with AEs and SAEs
Summary
The purpose of this study is to measure the long-term safety and efficacy profile of LTP001
 in participants with pulmonary arterial hypertension (PAH). The study offers participants who
 had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive
 LTP001 (whether they were on LTP001 or not). Unblinding of the treatment received in
 CLTP001A12201 is generally not needed, but can occur on request by the investigator.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05764265
Non-Device Trial